Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hodgkin Disease × Lenograstim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Breast Neoplasms 3 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Seminoma 1 Prostate Cancer Metastatic 1 Ovarian Neoplasms 1 Neutropenia 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Endodermal Sinus Tumor 1 Central Nervous System Neoplasms 1 Castrate Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 176 fludarabine phosphate 99 Etoposide 99 Peripheral Blood Stem Cell Transplantation 85 Filgrastim 79 Doxorubicin 76 Mycophenolic Acid 75 Melphalan 72 Whole-Body Irradiation 70 Brentuximab Vedotin 67 Radiotherapy 66 fludarabine 63 Tacrolimus 62 Busulfan 60 Vinblastine 56 Cyclosporine 55 Rituximab 54 Gemcitabine 47 Dacarbazine 47 Bleomycin 46 Granulocyte Colony-Stimulating Factor 45 Vincristine 42 Prednisone 41 Antilymphocyte Serum 41 Cytarabine 40 Methotrexate 37 Nivolumab 35 Carmustine 34 pembrolizumab 31 Sirolimus 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡